The role of multi-parametric MRI in loco-regional staging of men diagnosed with early prostate cancer

Current Opinion in Urology

Volumn 25, Issue 6, 2015, Pages 510-517

  Appayya, Mrishta Brizmohun ^a   Johnston, Edward William ^b   Punwani, Shonit ^a,b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Early prostate cancer; Loco regional staging; Multi parametric MRI

Indexed keywords

ARTIFACT; BLADDER SPHINCTER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER STAGING; DIFFUSION WEIGHTED IMAGING; HUMAN; MALE; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; SEMINAL VESICLE; SUSCEPTIBILITY WEIGHTED IMAGING; BIOPSY; EARLY CANCER DIAGNOSIS; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

BIOPSY; DIFFUSION MAGNETIC RESONANCE IMAGING; EARLY DETECTION OF CANCER; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84943144852     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000215     Document Type: Review

References (64)

1. National Institute for Health and Care Excellence, 2014. http://www.nice.or-g.uk/guidance/cg175/chapter/1-recommendations. [cited 2015]
2. Fütterer JJ, Briganti A, De Visschere P, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol 2015; doi: 10.1016/j.eururo. 2015.01.013. [Epub ahead of print]
3. Schoots IG, Petrides N, Giganti F, et al. Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol 2015; 67:627-636.
4. Barchetti F, Panebianco V. Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and postradiation therapy. Biomed Res Int 2014; 2014:316272; 1-23 doi: 10.1155/2014/316272.
5. Sankineni S, Osman M, Choyke PL. Functional MRI in prostate cancer detection. Biomed Res Int 2014; 2014:590638; 1-8 doi: 10.1155/2014/590638.
6. Punwani S. Diffusion weighted imaging of female pelvic cancers: concepts and clinical applications. Eur J Radiol 2011; 78:21-29.
7. Alonzi R, Padhani AR, Allen C. Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol 2007; 63:335-350.
8. Verma S, Rajesh A, Fütterer JJ, et al. Prostate MRI and 3D MR spectroscopy: how we do it. Am J Roentgenol 2010; 194:1414-1426.
9. Riches SF, Payne GS, Morgan VA, et al. Multivariate modelling of prostate cancer combining magnetic resonance derived T2, diffusion, dynamic contrast-enhanced and spectroscopic parameters. Eur Radiol 2015; 25:1247-1256.
10. Hoang Dinh A, Souchon R, Melodelima C, et al. Characterization of prostate cancer using T2 mapping at 3T: a multiscanner study. Diagn Intervent Imaging 2015; 96:365-372. doi: 10.1016/j.diii.2014.11.016.
11. Woodfield CA, Tung GA, Grand DJ, et al. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. Am J Roent-genol 2010; 194:W316-W322.
12. Kim JY, Kim SH, Kim YH, et al. Low-risk prostate cancer: the accuracy of multiparametric MR imaging for detection. Radiology 2014; 271:435-444.
13. European Society ofUro-Radiologists. PI-RADS v2 2015. http://www.esur.org/fileadmin/content/user-upload/PIRADS-v2-20141223.pdf. [cited 2015]
14. Platzek I, Borkowetz A, Toma M, et al. Multiparametric prostate magnetic resonance imaging at 3 t: failure of magnetic resonance spectroscopy to provide added value. J Comput Assist Tomogr 2015. [Epub ahead of print]
15. Kirkham APS, Haslam P, Keanie JY, et al. Prostate MRI: who, when, and how? Report from a UK consensus meeting. Clin Radiol 2013; 68:1016-1023.
16. De Visschere P, Nezzo M, Pattyn E, et al. Prostate magnetic resonance spectroscopic imaging at 1.5tesla with endorectal coil versus 3. 0tesla without endorectal coil: comparison of spectral quality. Clin Imaging 2015; 39:636-641.
17. Turkbey B, Merino MJ, Gallardo EC, et al. Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: correlation with whole-mount histopathology. J Magn Reson Imaging 2014; 39:1443-1448.
18. Powell DK, Kodsi KL, Levin G, et al. Comparison of comfort and image quality with two endorectal coils in MRI of the prostate. J Magn Reson Imaging 2014; 39:419-426.
19. Scheenen TW, Rosenkrantz AB, Haider MA, Fütterer JJ. Multiparametric magnetic resonance imaging in prostate cancer management: current status and future perspectives. Invest Radiol 2015; 50:594-600. doi: 10.1097/ RLI.0000000000000163.
20. Puech P, Sufana-Iancu A, Renard B, Lemaitre L. Prostate MRI: can we do without DCE sequences in 2013? Diagn Interv Imaging 2013; 94:1299-1311.
21. Osman M, Shebel H, Sankineni S, et al. Whole prostate volume and shape changes with the use of an inflatable and flexible endorectal coil. Radiol Res Pract 2014; 2014:903747. doi: 10.1155/2014/903747.
22. Kim BS, Kim TH, Kwon TG, Yoo ES. Comparison of pelvic phased-array versus endorectal coil magnetic resonance imaging at 3 Tesla for local staging of prostate cancer. Yonsei Med J 2012; 53:550-556.
23. Tan CH, Hobbs Bp Fau-Wei W, Wei W Fau-Kundra V, Kundra V. Dynamic contrast-enhanced MRI for the detection of prostate cancer: meta-analysis. AJR Am J Roentgenol 2015; 204:W439-W448. doi: 10.2214/AJR. 14.13373.
24. Abd-Alazeez M, Ahmed HU, Arya M, et al. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level-Can it rule out clinically significant prostate cancer? Urol Oncol 2014; 32:45.e17-22. doi: 10.1016/j.urolonc.2013.06.007.
25. Arumainayagam N, Ahmed HU, Moore CM, et al. Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. Radiology 2013; 268:761-769.
26. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. Am J Roentgenol 2007; 188:1622-1635.
27. Malayeri AA, El Khouli RH, Zaheer A, et al. Principles and applications of diffusion-weighted imaging in cancer detection, staging, and treatment follow-up. Radiographics 2011; 31:1773-1791.
28. Bollineni VR, Kramer G, Liu Y, et al. A literature review of the association between diffusion-weighted MRI derived apparent diffusion coefficient and tumouraggressivenessinpelvic cancer. Cancer Treat Rev 2015;41:496-502.
29. Wetter A, Nensa F, Lipponer C, et al. High and ultra-high b-value diffusion-weighted imaging in prostate cancer: a quantitative analysis. Acta Radiol 2015; 56:1009-1015. doi: 10.1177/0284185114547900.
30. Rosenkrantz AB, Kim S, Campbell N, et al. Transition zone prostate cancer: revisiting the role of multiparametric MRI at 3 T. Am J Roentgenol 2015; 204:W266-W272.
31. Tamada T, Kanomata N, Sone T, et al. High b value (2,000 s/mm2) diffusion-weighted magnetic resonance imaging in prostate cancer at 3 Tesla: comparison with 1,000 s/mm2 for tumor conspicuity and discrimination of aggressiveness. PLoS One 2014; 9:e96619.
32. Hamy VW-SS, Atkinson D, Punwani S, editors. Apparent diffusion coefficient estimation in prostate DW-MRI using maximum likelihood. 20th Annual Meeting of the International Society for Magnetic Resonance in Medicine, Melbourne; 2012.
33. Rouvière O, Raudrant A, Ecochard R, et al. Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur Radiol 2003; 13:931-942.
34. Johnson LM, Turkbey B, Figg WD, Choyke PL. Multiparametric MRI in prostate cancer management. Nat Rev Clin Oncol 2014; 11:346-353.
35. Khalifa F, Soliman A, El-Baz A, et al. Models and methods for analyzing DCE-MRI: a review. Med Phys 2014; 41:124301. doi: 10.1118/1.4898202.
36. Kobus T, Wright Aj Fau-Scheenen TWJ, Scheenen Tw Fau-Heerschap A, Heerschap A. Mapping of prostate cancer by 1H MRSI. NMR Biomed 2014;27:39-52. doi: 10.1002/nbm.2973.
37. Eggener SE, Badani K, Barocas DA, et al. Gleason 6 prostate cancer: translating biology into population health. J Urol 2015; pii: S0022-5347(15)03689-7. doi: 10.1016/j.juro.2015.01.126. [Epub ahead of print] Review.
38. Ahmed HU, Hu Y, Carter T, et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol 2011; 186:458-464.
39. Ahmed HU. Introduction: targeting the lesion, not the organ. Urol Oncol Semin Original Investig 2014; 32:901-902.
40. Volkin D, Turkbey B, Hoang AN, et al. Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers. BJU Int 2014; 114 (6b):E43-E49.
41. Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison ofMR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. J Am Med Assoc 2015; 313:390-397.
42. Latifoltojar A, Dikaios N, Ridout A, et al. Evolution of multiparametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate. Prostate Cancer Prostatic Dis 2015; doi: 10.1038/pcan.2015.33. [Epub ahead of print]
43. Abd-Alazeez M, Ahmed HU, Arya M, et al. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level: can it rule out clinically significant prostate cancer? Urol Oncol 2014; 32:45.e17-22. doi: 10.1016/j.urolonc.2013.06.007.
44. Krughoff K, Eid K, Phillips J, et al. The accuracy of prostate cancer localization diagnosed on transrectal ultrasound-guided biopsy compared to 3-dimen-sional transperineal approach. Adv Urol 2013; 2013:249080. doi: 10.1155/ 2013/249080.
45. Barrett T, Vargas HA, Akin O, et al. Value of the hemorrhage exclusion sign on T1-weighted prostate MR images for the detection of prostate cancer. Radiology 2012; 263:751-757.
46. Mikel Hubanks J, Boorjian SA, Frank I, et al. The presence of extracapsular extension is associated with an increased risk of death from prostate cancer after radical prostatectomy for patients with seminal vesicle invasion and negative lymph nodes. Urol Oncol 2014; 32:26.e1-7. doi: 10.1016/j.urolonc. 2012.09.002.
47. Cornud F, Rouanne M, Beuvon F, et al. Endorectal3D T2-weighted1mm-slice thickness MRI for prostate cancer staging at 1.5Tesla: should we reconsider the indirect signs of extracapsular extension according to the D'Amico tumor risk criteria? Eur J Radiol 2012; 81:e591-e597.
48. Renard-Penna R, Rouprêt M, Comperat E, et al. Accuracy of high resolution (1.5 tesla) pelvic phased array magnetic resonance imaging (MRI) in staging prostate cancer in candidates for radical prostatectomy: results from a prospective study. Urol Oncol 2013; 31:448-454.
49. Feng TS, Sharif-Afshar AR, Smith SC, et al. Multiparametric magnetic resonance imaging localizes established extracapsular extension of prostate cancer. Urol Oncol 2015; 33:109.e15-22. doi: 10.1016/j.urolonc. 2014.11.007.
50. Barentsz JO, Richenberg J, Fau - Clements R, et al. ESUR prostate MR guidelines. Eur Radiol 2012; 22:746-757. doi: 10.1007/s00330-011-2377-y.
51. Seminal vesicle invasion in prostate cancer: evaluation by using multipara-metric endorectal MR imaging. Radiology 2013; 267:797-806.
52. Ploussard G, Rotondo S, Salomon L. The prognostic significance of bladder neck invasion in prostate cancer: is microscopic involvement truly a T4 disease? BJU Int 2010; 105:776-781.
53. Magi-Galluzzi C, Evans AJ, Delahunt B, et al. International Society of Urolo-gical Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Mod Pathol 2011; 24:26-38.
54. Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008; 63:387-395.
55. van den Bergh L, Lerut E, Haustermans K, et al. Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement. Urol Oncol 2015; 33:109.e23-31. doi: 10.1016/j.urolonc.2014.11.008.
56. Yakar D, Debats OA, Bomers JG, et al. Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer. J Magn Reson Imaging 2012; 35:20-31.
57. Rowe SP, Gage KL, Faraj SF, et al. 18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med 2015; 56:1003-1010. doi: 10.2967/jnumed.115.154336.
58. Costelloe CM1, Madewell JE, Kundra V, et al. Conspicuity of bone metastases on fast Dixon-based multisequence whole-body MRI: clinical utility per sequence. Magn Reson Imaging 2013; 31:669-675. doi: 10.1016/j.mri. 2012.10.017.
59. Pasoglou V, Michoux N, Peeters F, et al. Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease. Radiology 2015; 275:155-166.
60. Pasoglou V, Larbi A, Collette L, et al. One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified 'all-in-one' imaging approach? Prostate 2014; 74:469-477.
61. Abd-Alazeez M, Ahmed HU, Arya M, et al. Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology? Urol Oncol Semin Original Investig 2014; 32:741-747.
62. Ahmed HU, Dickinson L, Charman S, et al. Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. Eur Urol 2015; pii: S0302-2838(15)00073-1. doi: 10.1016/j.eururo. 2015.01.030. [Epub ahead of print]
63. Punwani S, Emberton M, Walkden M, et al. Prostatic cancer surveillance following whole-gland high-intensity focused ultrasound: comparison of MRI and prostate-specific antigen for detection of residual or recurrent disease. Br J Radiol 2012; 85:720-728.
64. Moore CM, Ridout A, Emberton M. The role of MRI in active surveillance of prostate cancer. Curr Opin Urol 2013; 23:261-267.